Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Marizomib - Celgene Corporation

Drug Profile

Marizomib - Celgene Corporation

Alternative Names: MRZ; NPI-0052; Salinosporamide A

Latest Information Update: 28 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nereus Pharmaceuticals
  • Developer Canadian Cancer Trials Group; Celgene Corporation; European Organisation for Research and Treatment of Cancer; Triphase Accelerator Corporation
  • Class Anti-inflammatories; Antineoplastics; Lactones; Pyrroles; Small molecules
  • Mechanism of Action Apoptosis stimulants; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Glioblastoma
  • Phase II Multiple myeloma
  • No development reported Cancer; Lymphoma; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for phase-I development in Glioblastoma(Combination therapy, Late-stage disease, Metastatic disease, Newly diagnosed) in Canada (IV)
  • 28 Oct 2019 No recent reports of development identified for phase-I development in Glioblastoma(Combination therapy, Late-stage disease, Metastatic disease, Newly diagnosed) in Switzerland (IV)
  • 28 Oct 2019 No recent reports of development identified for phase-I development in Glioblastoma(Combination therapy, Late-stage disease, Metastatic disease, Newly diagnosed) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top